For decades, millions of women have sat in doctors’ offices clutching a diagnosis that felt incomplete, or received no diagnosis at all. They were told they had a condition named for something many of them never even had: cysts. A name written nearly a century ago, by two surgeons in Chicago who were peering at enlarged ovaries under surgical lights and drawing conclusions that medicine would spend the next 90 years quietly complicating. That name is now being retired.
The change happened on May 12, 2026, and it is the result of something unusual in modern medicine: a decade and a half of determined, genuinely global collaboration, driven not just by researchers but by the hundreds of thousands of women who had lived, unheard, inside a diagnostic label that never really fit.
What comes next may reshape how doctors, researchers, and patients understand a condition that touches nearly every system in the body: hormones, metabolism, mental health, the heart, the skin. The story behind the rename is as important as the rename itself.
A Quick Overview:
Polycystic ovary syndrome (PCOS), a condition affecting more than 170 million people worldwide, has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS) following a landmark global consensus study published in The Lancet. The revised name was introduced in a paper published in The Lancet and presented at the European Congress of Endocrinology in Prague. The name change journey took 14 years of global collaboration between experts and those with lived experience. At its core, the rename is a correction: a formal acknowledgment that the old term was scientifically inaccurate, clinically misleading, and, for too many women, a barrier to appropriate care.
A Name That Was Never Quite Right
To understand why the rename matters, you have to understand why “polycystic ovary syndrome” was always the wrong name.
The “cysts” behind polycystic ovary syndrome first received widespread attention when they were described by two Chicago surgeons in 1935. Irving Stein and Michael Leventhal were investigating infertility in women, and they noticed during surgery that their patients’ ovaries were enlarged and contained numerous small, cyst-like structures. These “cysts,” however, would turn out to be something else entirely: ovarian follicles that had stopped growing. Today, we know that these underdeveloped eggs aren’t a unique feature of PMOS, and they rarely require surgical removal.
The name suggested the presence of pathological ovarian cysts, which are not a feature of the condition. The “cysts” seen on ultrasound are arrested follicles – underdeveloped eggs that never completed their journey. The distinction matters enormously. A cyst is a fluid-filled sac that can rupture and cause acute pain. An arrested follicle is a hormonal problem, not a structural one. Calling the condition “polycystic” sent patients, and often their doctors, chasing the wrong culprit.
The understanding of the disorder among scientists has changed, but the understanding among patients and doctors has lagged, says Rachel Morman, chair of PCOS charity Verity UK and a patient with the condition herself. “There was still a really, really large component of women with the condition that still believed that they had ovarian cysts, and, frighteningly, a huge number of professionals that also believed that,” she says.
The consequences of that confusion went well beyond semantics. The term PCOS was inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy framing. According to the World Health Organization, PCOS affects an estimated 10 to 13 percent of reproductive-aged women, and up to 70 percent of women with PCOS worldwide do not know they have this condition.
The Anatomy of a Rename: 14 Years in the Making
The path from PCOS to PMOS was not fast, simple, or undisputed. The journey to a new name started in October 2015, with a fight: at a meeting in Sicily, experts brought together to discuss renaming PCOS vehemently disagreed with one another.
What followed was one of the most extensive patient and clinician engagement processes in the history of medical nomenclature. Building on earlier surveys administered in 2017 and 2023, a team led by Helena Teede at Monash University in Australia developed a third survey, which was administered to nearly 15,000 stakeholders in 2025. Overall, about 22,000 people across the globe, including doctors, researchers, patients, and charities, shared their thoughts on a new name.
Professor Helena Teede, Director of Monash University’s Monash Centre for Health Research and Implementation and an endocrinologist at Monash Health, led the name change process after spending decades researching the condition and seeing the patient impacts firsthand. Teede led the process alongside International Androgen Excess and Polycystic Ovary Syndrome Society (AE-PCOS Society) President, Professor Terhi Piltonen, an international co-lead from Oulu University and Oulu University Hospital, Finland, AE-PCOS Society Executive Director Anuja Dokras from the United States, and Chair of Verity (PCOS UK) Rachel Morman, with 56 patient and professional organizations, including the Endocrine Society.
Asked what they wanted a new name to accomplish, the primary response was avoiding stigma, followed by ease of communication and scientific accuracy. Respondents preferred an accurate, descriptive name over a generic one, and indicated a strong interest in including the involvement of the endocrine system in the condition.
Three candidate names went through final testing. The winning candidate, PMOS, was chosen in a landslide earlier this year over two other candidates: endocrine metabolic ovulatory syndrome and ovulatory metabolic endocrine syndrome. Retaining the word “ovarian” was deliberate, though not without debate. Teede explained that “ovarian encompasses a lot more,” including “the hormonal changes in the ovary and the follicle responses in the ovary,” and that using “reproductive” in the title instead “was felt, especially in many cultures and world regions, to be too stigmatizing and likely to cause harm.”
The new name was the nearly unanimous choice of the panel of clinicians, researchers, and patient advocates, although there remains some dissatisfaction, in part because retaining “ovarian” in the name doesn’t allow for the possibility, suggested by some early research, of a male form of the syndrome.
What the New Name Actually Means – PMOS
Each word in PMOS was chosen deliberately to correct a specific flaw in its predecessor.
Polyendocrine
The new name recognizes that the condition is underpinned by multiple interacting hormonal disturbances, including insulin, androgens, and neuroendocrine hormones, rather than being an isolated ovarian disorder. The prefix “poly” combined with “endocrine” signals that several hormone-producing glands are involved, not just the ovaries. The first word in the new name, polyendocrine, relates to how the condition impacts and involves multiple endocrine (or hormone) glands.
Metabolic
This addition may carry the most weight clinically. Dr. Melanie Cree, a pediatric endocrinologist and professor at the University of Colorado Anschutz, noted that the focus has often been on fertility and reproduction, at the expense of other effects of the disorder. “The majority of women don’t get appropriate metabolic screening,” she says, meaning serious health problems can be missed, sometimes for years. For instance, in adolescents with PMOS, “cardiovascular disease starts very early.” But when teenagers are diagnosed, sometimes “no discussion about metabolic conditions, no screening for metabolic conditions occurs.”
Beyond reproductive concerns, the condition carries an elevated lifetime risk of obesity, metabolic syndrome, and type 2 diabetes. The condition involves interacting disturbances in insulin signaling, androgen production, neuroendocrine pathways, and ovarian function. These abnormalities contribute not only to infertility and menstrual dysfunction, but also to obesity, type 2 diabetes, cardiovascular disease risk, mental health conditions, and pregnancy complications.
Ovarian
Keeping “ovarian” in the name preserves a meaningful clinical signal without overstating it. The ovaries are involved, but as participants in a wider hormonal disruption, not as the origin or the sole affected organ. The new designation acknowledges the condition’s hormonal complexity across multiple endocrine axes (polyendocrine), incorporates its metabolic and cardiometabolic burden, and retains reference to ovarian involvement without reducing the condition to a reproductive disorder.
For readers interested in understanding how insulin resistance connects to hormonal disruption, a related overview on theheartysoul.com details the signs and metabolic consequences worth knowing.
The Cost of the Wrong Name: Delayed Diagnoses and Missed Risks
The damage done by an inaccurate name is not abstract. It is measurable, and it has accumulated over decades.
As a name, PCOS had several limitations, including providing an inaccurate description of the condition. This led patients to attribute ovarian cysts to PCOS and risk being underdiagnosed for other conditions, said Rachel Morman of Verity. Doctors who focused on the cystic presentation could dismiss patients who didn’t present with visible cysts, even when those same patients were suffering from the metabolic and fertility problems the condition is known to cause.
Receiving a PCOS diagnosis can be slow and costly. Nearly 50 percent of patients wait one to two years for a diagnosis. That delay has real consequences. More than half of women with PCOS will develop diabetes or prediabetes before the age of 40.
The mental health toll is equally significant and has been equally neglected. Around 40 percent of women with PCOS are known to experience depression or anxiety, according to multiple studies. Despite this, mental health conditions often go unnoticed by obstetrician-gynecologists when identifying complications linked with PCOS. This oversight contributes to the dissatisfaction many women with PCOS express regarding the psychological counseling they receive, stemming largely from limited awareness among physicians of these mental health links.
PMOS is the new name for the condition previously known as PCOS, which impacts 1 in 8, or more than 170 million women worldwide. More than 50 patient and professional organizations, including the Endocrine Society, took part in the process to develop the new name. Yet for decades, research funding was long limited to sources focused on ovarian health, meaning the broader metabolic burden went largely unstudied and underfunded.
What the Rename Changes, and What It Doesn’t
The name change does not immediately alter the diagnostic criteria used by physicians. Under the latest criteria, PMOS is indicated if patients meet 2 out of 3 criteria: excess male hormones called androgens, irregular menstrual cycles, and high levels of anti-Müllerian hormone (AMH) in blood, or ovaries with many arrested follicles seen on ultrasound.
What the rename is expected to change, over time, is the clinical frame: the way doctors think about what they are treating, and what they should screen for. Dr. Mickey Coffler, OB-GYN and fertility specialist at HRC Fertility, said: “Recognizing PMOS as a ‘polyendocrine’ condition acknowledges that infertility is driven by multiple interacting hormonal disturbances, including insulin and neuroendocrine hormones, rather than just an isolated ovarian disorder.”
Thinking of PMOS as a metabolic disorder could mean using treatments like GLP-1s, a class of medications also used for type 2 diabetes and obesity, in these patients. This would mark a meaningful contrast to the mainly reproductive-focused treatment options currently available. Implementation of the PMOS terminology is already underway and will occur over a planned 3-year transition period. The strategy includes updates to clinical guidelines, electronic health records, educational materials, International Classification of Diseases systems, and future research publications.
A suite of additional academic papers by the same experts are being published on the need for and implications of the name change on a variety of issues, including adolescent health, maternal health, clinical practice, policy reform, and research.
Read More: Does Sugar Consumption Affect PMOS?
Voices of Those Living With It
For many patients, the rename is being felt less as a bureaucratic update and more as a long-overdue acknowledgment.
Lorna Berry, an Australian woman who has PMOS and played a key role in the renaming process, said the result will be life-changing. “This is about accountability and progress,” she said. “It is about my daughters, their daughters, and the countless women yet to be born. We deserve clarity, understanding, and equitable healthcare from the very beginning.”
Rachel Morman, Chair of Verity (PCOS UK), said: “It is fantastic that the new name now leads with hormones and recognizes the metabolic dimension of the condition. This shift will reframe the conversation and demand that it is taken as seriously as the long-term, complex health condition it is.”
Patient advocates have also pointed to what makes this effort stand out. As Dr. Cree noted, “What makes this effort especially powerful is that it reflects the voices of thousands of patients and clinicians from around the world.”
There are voices expressing measured caution, too. Some in the field worry that the new name still doesn’t quite capture the latest understanding of the condition. The authors of the consensus paper themselves acknowledged several limitations, including lower participation from some low- and middle-income countries and the use of voluntary survey participation, which may introduce selection bias. However, they noted that naming preferences were generally consistent across geographic regions. These are legitimate concerns, but they don’t diminish the scale of what has been achieved.
What This Means for You
The PCOS-to-PMOS rename is the most consequential development in women’s hormonal health in a generation. Here is what it means in practical terms.
The condition is far broader than its old name implied. PMOS is characterized by fluctuations in hormones, with impacts on weight, metabolic and mental health, skin, and the reproductive system. If you or someone you know has been diagnosed with PCOS and has received only reproductive-focused care, revisiting that with a doctor who can assess metabolic and cardiovascular risks is a reasonable next step.
The diagnosis is still made the same way for now: two of three criteria, being androgen excess, irregular cycles, or elevated AMH and arrested follicles on ultrasound. The name has changed; the diagnostic threshold has not. Expect clinical guidelines to evolve as the three-year transition period progresses.
The 70 percent undiagnosed rate is the number that demands the most urgent attention. An estimated 10 to 13 percent of reproductive-age women around the world are impacted by PCOS, but an estimated 70 percent don’t know they have it, according to the WHO. If you experience irregular periods, unexplained weight gain or difficulty losing weight, acne that doesn’t respond to typical treatments, excess facial or body hair, or persistent fatigue, these are all reasons to ask your doctor about PMOS specifically, by name.
Language in medicine shapes action. Advocates say the change will open the door to more sources of research funding for the disorder, as well as clarify its true nature for patients and doctors, for whom the so-called cysts have long been a source of confusion. A name that more accurately reflects what PMOS actually is, a complex hormonal and metabolic condition, gives researchers a broader mandate, gives insurers and policymakers clearer frameworks, and gives patients better language to advocate for themselves.
The condition has not changed. It was never just about ovaries, and it was never just about cysts. Now, at last, its name says so.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human edito